TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Endoscopic Peroral Myotomy for Treatment of Achalasia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Patient with symptomatic achalasia and pre-op barium swallow, manometry and esophagal-gastro-duodenoscopy which are consistent with the diagnosis~* persons of age \> 18 years with medical indication for surgical myotomy or Endoscopic balloon dilatation~* Signed written informed consent.~Exclusion criteria:~* Patients with previous surgery of the stomach or esophagus~* Patients with known coagulopathy~* Previous achalasia-treatment with surgery~* Patients with liver cirrhosis and/or esophageal varices~* Active esophagitis~* Eosinophilic esophagitis~* Barrett's esophagus~* Pregnancy~* Stricture of the esophagus~* Malignant or premalignant esophageal lesion~* Candida esophagitis~* Hiatal hernia \> 2cm

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Peroral Endoscopic Myotomy (Type: EXPERIMENTAL): Patients with achalasia who are designed to either get balloon dilatation or have botulinum toxin injection, or to have surgical intervention (Heller myotomy)for treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Web-Based Delivery of MOVE! to Veterans With Serious Mental Illness (SMI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnostic and Statistical Manual (DSM-IV) diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, recurrent major depressive disorder with psychosis, or PTSD;~* age 18 and over;~* no psychiatric hospitalization during the month prior to enrollment;~* receipt of an antipsychotic medication for at least 3 months prior to enrollment;~* BMI of 30 or higher, or BMI of 28 or higher if 10 pounds of recent weight gain;~* medical clearance to participate from a VA physician;~* control over diet.~Exclusion Criteria:~* any medical condition for which a weight program is contraindicated;~* history of bariatric surgery;~* pregnant and nursing mothers;~* a diagnosis of dementia;~* not able to provide informed consent by self or legally appointed representative.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): in-person MOVE! SMI
- Arm 2 (Type: EXPERIMENTAL): web-based MOVE! SMI
- Arm 3 (Type: NO_INTERVENTION): usual care + educational handouts regarding weight loss

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed malignancy not amenable to curative surgery, radiotherapy, or chemotherapy~* Tumor types may include any of the following:~  * Any solid tumor including, but not limited to, head and neck, breast, lung, gastrointestinal, genitourinary, melanoma, and sarcoma~ * Primary CNS neoplasms if the following are true:~    * Received primary radiotherapy~   * No concurrent corticosteroids or has been on a stable corticosteroid dose for at least 30 days~   * No concurrent enzyme-inducible anti-epileptic medications (i.e., carbamazepine or phenytoin)~ * Multiple myeloma~ * Non-Hodgkin's lymphoma~* No refractory or relapsed acute or chronic leukemia~* Measurable or evaluable disease~* No life-prolonging therapy available~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age~* 18 and over~Sex~* Male or female~Menopausal status~* Not specified~Performance status~* ECOG 0-1~Life expectancy~* At least 4 months~Hematopoietic~* WBC at least 4,000/mm\^3~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 10 g/dL~Hepatic~* Bilirubin no greater than upper limit of normal (ULN)~* AST and/or ALT no greater than 2.5 times ULN if alkaline phosphatase less than ULN OR~* Alkaline phosphatase no greater than 4 times ULN if AST/ALT less than ULN~Renal~* Creatinine no greater than 1.5 mg/dL OR~* Creatinine clearance at least 60 mL/min~Cardiovascular~* No New York Heart Association class III or IV heart disease~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use 2 effective methods of contraception 4 weeks before, during, and 4 weeks after study~* Willing and able to comply with FDA-mandated STEPS program~* No peripheral neuropathy grade 2 or greater~* No prior severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered~* No more than 2 prior courses of mitomycin~Endocrine therapy~* See Disease Characteristics~Radiotherapy~* At least 4 weeks since prior large-field radiotherapy and recovered~Surgery~* Not specified~Other~* At least 3 weeks since other prior anticancer therapy and recovered

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed clinical diagnosis of ulcerative colitis (UC) at least 3 months before screening~* Moderately to severely active UC as defined by Mayo score~* History of inadequate response to or failure to tolerate conventional therapy~* Has screening laboratory test results within the study protocol defined parameters~* A woman of childbearing potential must have a negative highly sensitive serum (beta human chorionic gonadotropin) pregnancy test result at screening and a negative urine pregnancy test result at Week 0~Exclusion Criteria:~* Has severe extensive colitis as defined in the study protocol~* Has UC limited to the rectum only or to less than (\<) 20 centimeter (cm) of the colon~* Has a history of latent or active granulomatous infection, including histoplasmosis or coccidioidomycosis, before screening~* Has any known malignancy or has a history of malignancy (with the exception of basal cell carcinoma; squamous cell carcinoma in situ of the skin; or cervical carcinoma in situ that has been treated with no evidence of recurrence; or squamous cell carcinoma of the skin that has been treated with no evidence of recurrence within 5 years before screening)~* Has known allergies, hypersensitivity, or intolerance to guselkumab or golimumab or their excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Combination Therapy (Type: EXPERIMENTAL): Participants will receive guselkumab Dose 1 as intravenous (IV) infusion and Dose 2 as subcutaneous (SC) injection; and golimumab Dose 1 and Dose 2 as SC injection and placebo to maintain the blind.
- Monotherapy: Guselkumab (Type: EXPERIMENTAL): Participants will receive guselkumab Dose 1 as IV infusion, Dose 2 as SC injection and placebo to maintain the blind.
- Monotherapy: Golimumab (Type: ACTIVE_COMPARATOR): Participants will receive golimumab Dose 1 and Dose 2 as SC injection and placebo to maintain the blind.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open Label Study of Levetiracetam in Japanese Pediatric Patients With Partial Seizures

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has partial Epilepsy and the diagnosis must be confirmed in the last 6 months~* The patients must be on a stable 1 or 2 anti-epileptic drug(s) treatment during the 4 weeks prior to Baseline and must have at least 8 partial seizures during the 8-week prospective Baseline Period~* Patient at the age of 4 to 16 years, and at the body weight of 11 to 82 kg~Exclusion Criteria:~* The patient has a treatable seizure etiology~* The patient has Epilepsy secondary to a progressive cerebral disease or any other progressively neurodegenerative disease, including Rasmussen and Landau-Kleffner diseases~* The patient has a history of status Epilepticus during the 3 months prior to Visit 1~* The patient has a past and present history of pseudo seizures~* The patient has a current diagnosis of Lennox-Gastaut syndrome

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Levetiracetam (Type: EXPERIMENTAL): Open-label, single-arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* A male or female participant with a clinical diagnosis of PFIC Type 1 or 2 and with a body weight above 5 kg~* Participant must have clinical genetic confirmation of PFIC-1 or PFIC-2~* Participant must have elevated serum bile acid (s-BA) concentration~* Participant must have history of significant pruritus and a caregiver reported observed scratching in the eDiary~* Participant and/or legal guardian must sign informed consent (and assent) as appropriate.~* Participants will be expected to have a consistent caregiver(s) for the duration of the study~* Caregivers and age-appropriate participants (≥8 years of age) must be willing and able to use an eDiary device as required by the study~Key Exclusion Criteria:~* Participant with pathologic variations of the ABCB11 gene that predict complete absence of the bile salt export pump (BSEP) protein~* Participant with past medical history or ongoing presence of other types of liver disease including, but not limited to, the following:~  1. Biliary atresia of any kind~ 2. Benign recurrent intrahepatic cholestasis, indicated by any history of normal s BAs~ 3. Suspected or proven liver cancer or metastasis to the liver on imaging studies~ 4. Histopathology on liver biopsy that is suggestive of alternate non-PFIC related etiology of cholestasis~* Participant with past medical history or ongoing chronic diarrhea~* Any participant with suspected or confirmed cancers except for basal cell carcinoma~* Participant with a past medical history of chronic kidney disease with an impaired renal function and a glomerular filtration rate \<70 mL/min/1.73 m\^2~* Participant with surgical history of disruption of the enterohepatic circulation (biliary diversion surgery) within 6 months prior to start of Screening Period~* Participant has had a liver transplant or a liver transplant is planned within 6 months of randomization~* Decompensated liver disease~* Participant suffers from uncontrolled, recalcitrant pruritic condition other than PFIC~* Participant who has been previously treated with an IBAT inhibitor whose pruritus has not responded to treatment

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- A4250 low dose (Type: EXPERIMENTAL): Capsules for oral administration (40 ug/kg) once daily for 24 weeks
- A4250 high dose (Type: EXPERIMENTAL): Capsules for oral administration (120 ug/kg) once daily for 24 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Capsules for oral administration (to match active) once daily for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female between the ages of 16 and 74 diagnosed with Fabry disease.~* Confirmed mutant form of α-galactosidase A shown to be responsive to migalastat in vitro.~* Participant has never been treated with enzyme replacement therapy (ERT) or has not received ERT for 6 consecutive months or longer before the screening visit for the study.~* Urine GL-3 ≥4 times the upper limit of normal at screening.~* Participants taking angiotensin converting enzyme inhibitors or angiotensin receptor blockers must be on a stable dose for a minimum of 4 weeks before the baseline visit.~* Females who can become pregnant and all males agree to be sexually abstinent or use medically accepted methods of birth control during the study and for 30 days after study completion.~* Participant is willing and able to provide written informed consent and assent, if applicable.~Exclusion Criteria:~* Participant has undergone or is scheduled to undergo kidney transplantation, or is currently on dialysis.~* Estimated glomerular filtration rate \<30 milliliters per minute per 1.73 meters squared (chronic kidney disease Stage 4 or 5) based on the Modification of Diet in Renal Disease equation at screening.~* Pregnant or breast-feeding.~* History of allergy or sensitivity to study medication (including excipients) or other iminosugars (for example, miglustat, miglitol).~* Participant is treated or has been treated with any investigational drug within 30 days of study start.~* Participant is currently treated or has ever been treated with migalastat.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Migalastat (Type: EXPERIMENTAL): Migalastat 150-mg capsule taken orally every other day (QOD) for 6 months and an open-label 6-month treatment extension, followed by an optional, 12-month, open-label treatment extension.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo capsule taken orally QOD for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Different TRansesophageal Echocardiography Guided thrOmbolytic Regimens for prosthetIc vAlve Thrombosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with prosthetic valve thrombosis~Exclusion Criteria:~* Large left atrial thrombus~* Recent (\<3 weeks) ischemic stroke~* Hemorrhagic stroke~* Early (\<4 days) postoperative period~* Traumatic accident \<4 weeks~* Bleeding diathesis †~* İntracranial mass~* Active internal bleed~* Aortic dissection

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rapid streptokinase (Type: ACTIVE_COMPARATOR): 3-hour infusion of 1.5 million units of streptokinase (16 patients, 16 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units).
- high dose tpa (Type: ACTIVE_COMPARATOR): 5-hour infusion of 90 mg t-PA(Tissue plasminogen activator) after 10 mg bolus (10 patients, 12 episodes), repeat once 24 hours later if needed (maximum total dose 200 mg)
- slow streptokinase (Type: ACTIVE_COMPARATOR): 24-hour infusion of 1.5 million units of streptokinase (41 patients, 41 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units).
- half-dose slow infusion tpa (Type: ACTIVE_COMPARATOR): 6-hour infusion of 50 mg t-PA (Tissue plasminogen activator) without bolus (27 patients, 27 episodes), repeat once 24 hours later up to 3 times if needed (maximum total dose 150 mg).
- low dose slow infusion tpa (Type: ACTIVE_COMPARATOR): 6-hour infusion of 25 mg t-PA(Tissue plasminogen activator) without bolus (108 patients, 124 episodes), repeat once 24 hours later up to 6 times if needed (maximum total dose 150 mg).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written consent of the patient, after informing~* Generalized MG of grade III, IV or V - Classification MGFA~* Follow-up on 15 months possible and accepted by patients~Exclusion Criteria:~* Age\<18 or \>80 years~* Pregnancy~* Myasthenia of grade I or II of MGFA~* Patients already treated with prednisone or azathioprine~* Contraindication for prednisone or azathioprine~* Other associated disease requiring a treatment with prednisone or azathioprine~* Weight \>100kg~* Invasive thymoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Starting dose Prednisone Azathioprine (Type: ACTIVE_COMPARATOR): Classical Strategy
- Starting dose Prednisone - Azathioprine (Type: ACTIVE_COMPARATOR): Rapid strategy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: D-serine Augmentation of Neuroplasticity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Age between 18 and 50~2. DSM-V diagnosis of schizophrenia or schizoaffective disorder~3. Willing to provide informed consent~4. Auditory Cognitive impairment demonstrated by:~   a .MCCB composite domain score less than or equal to 0.5 standard deviation below normal (T score less than or equal to 45) b. And at least one of the following:~  * MCCB verbal memory domain score less than or equal to 0.5 standard deviation below normal (T score less than or equal to 45)~  * Tone matching score of less than or equal to 77.7%~5. Clinically stable for 2 months (CGI less than or equal to 4)~6. Moderate or lower cognitive disorganization (PANSS P2 less than or equal to 4)~7. Medically stable for study participation~8. Willing to use qualified methods of contraception for the study duration and up to 2 months after its end~9. Fluent English speaker~10. Normal hearing~11. Visual acuity corrected to 20/30~12. An estimated Glomerular Filtration Rate (GFR) greater than or equal to 60~13. Taking an antipsychotic medication other than clozapine at a stable dose for at least 4 weeks~14. Judged clinically not to be at significant suicide or violence risk~Exclusion Criteria:~1. ECG abnormality that is clinically significant in the context of study participation in the opinion of the study cardiologist~2. Current clozapine use~3. Presence of positive history of unstable significant medical or neurological illness~4. Positive toxicology screen for any substances of abuse~5. Substance use disorder (excluding nicotine) within last 60 days~6. Pregnant women or women of child-bearing potential, who are either not surgically-sterile or for outpatients, using appropriate methods of birth control. Women of childbearing potential must have a negative serum -hCG pregnancy test at every visit.~7. Participation in study of investigational medication/device within 4 weeks~8. Subjects with suicidal ideation with intent or plan (indicated by affirmative answers to items 4 or 5 of the Suicidal Ideation section of the baseline C-SSRS) in the 6 months prior to screening or subjects who represent a significant risk of suicide in the opinion of the investigator Section

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- D-serine 80 mg/kg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- D-serine 100 mg/kg (Type: EXPERIMENTAL): None
- D-serine 120 mg/g (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immune Dysfunction in Allergic Asthma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Mild asthma, adults -~Exclusion Criteria:~children. on inhaled or systemic steroids~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- xolair (Type: EXPERIMENTAL): This is a single arm, parallel study examining differences of therapeutic outcomes of Xolair. Xolair is being examined as an intervention that might change the outcome of immunization.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete